Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Eleda in connection with the acquisition of Signalbolaget i Sverige AB
Mandate

Vinge has advised Eleda in connection with the acquisition of Signalbolaget i Sverige AB

April 07, 2025 Employment and Benefits M&A Real Estate and Construction Banking and Finance FDI Data protection and processing of personal data

Signalbolaget is involved in the development and maintenance of the Swedish railway network, with a focus on services within signaling technology. Signalbolaget is based in Borlänge, Sweden, has a turnover of approximately SEK 80 million and 50 employees.

The transaction is subject to customary regulatory approval.

Vinge’s team consisted mainly of Christina Kokko, Ellen Flygt and Philip Moré (M&A), Daniel Wendelsson and David Olander (FDI), Emil Lindwall and Louisa Fagarasan (Employment), Calle Tengwall Pagels and Ida Appelgren (Banking and finance), Hanna Kövamees and Wilma Hellman (Real Estate), Nicklas Thorgerzon (GDPR) and Johanna Engström (Transaction Support Senior Coordinator).

 

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025